| GLPG Stock | | | EUR 25.50 0.20 0.78% |
President
Dr. Andre Hoekema, Ph.D. is Member of the Executive Committee, Chief Business Officer at Galapagos NV. He joined Galapagos in March 2005 from Invitrogen Corporationrationration, where he was Managing Director of Corporationrationrate Development Europe. He has 20 years of biotech experience from positions at Molecular Probes Europe, Crucell, DSM Life Sciences and MOGEN and Genentech, Inc. Dr. Hoekema has a Doctorate in Philosophy degree from Leiden University and is the inventor of over 20 series of patent applications, resulting in 15 patents issued in the United States. Dr. Hoekema currently also serves as a member of the supervisory board of Mimetas B.V. and has previously served as a member of the supervisory board of VitalNext B.V.
| Age | 66 |
| Professional Marks | Ph.D |
| Phone | 32 1 534 29 00 |
| Web | https://www.glpg.com |
Hoekema has a Doctorate in Philosophy degree from Leiden University and is the inventor of over 20 series of patent applications, resulting in 15 patents issued in the United States.
Galapagos Management Efficiency
The company has return on total asset
(ROA) of
(0.0119) % which means that it has lost $0.0119 on every $100 spent on assets. This is way below average. Galapagos' management efficiency ratios could be used to measure how well Galapagos manages its routine affairs as well as how well it operates its assets and liabilities.
Galapagos NV has accumulated 27.91
M in total debt with debt to equity ratio
(D/E) of 0.01, which may suggest the company is not taking enough advantage from borrowing. Galapagos NV has a current ratio of 8.71, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Galapagos until it has trouble settling it off, either with new capital or with free cash flow. So, Galapagos' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Galapagos NV sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Galapagos to invest in growth at high rates of return. When we think about Galapagos' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 1 records | PRESIDENT Age |
| Henk Brinke | Koninklijke Ahold Delhaize | N/A |
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium. GALAPAGOS operates under Biotechnology classification in Netherlands and is traded on Amsterdam Stock Exchange. It employs 1397 people. Galapagos NV (GLPG) is traded on Euronext Amsterdam in Netherlands and employs 1,357 people.
Management Performance
Galapagos NV Leadership Team
Elected by the shareholders, the Galapagos' board of directors comprises two types of representatives: Galapagos inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Galapagos. The board's role is to monitor Galapagos' management team and ensure that shareholders' interests are well served. Galapagos' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Galapagos' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elizabeth Goodwin, VP Corporate Communications & Investor Relations | |
| Andre Hoekema, Senior Vice President - Corporate Development | |
| John Montana, Managing Argenta | |
| Michele MBA, Chief Board | |
| Walid AbiSaab, Member of the Executive Committee, Chief Medical Officer | |
| Marieke Vermeersch, Head Communication | |
| Chantal Tasset, Head Devel | |
| Sofie Gijsel, Head Relations | |
| MBA MBA, COO Pres | |
Galapagos Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Galapagos a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for Galapagos Stock Analysis
When running Galapagos' price analysis, check to
measure Galapagos' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galapagos is operating at the current time. Most of Galapagos' value examination focuses on studying past and present price action to
predict the probability of Galapagos' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galapagos' price. Additionally, you may evaluate how the addition of Galapagos to your portfolios can decrease your overall portfolio volatility.